Fig. 4

Comparison of adjusted annual change in PASP in historical control study. Comparison of adjusted annual changes in pulmonary artery systolic pressure (PASP) between the nintedanib groups and no antifibrotic therapy groups in idiopathic pulmonary fibrosis (IPF) patients with long-term oxygen treatment (LTOT) (left) and without LTOT (right). There were no significant differences between the nintedanib and no antifibrotic therapy groups (7.19 mmHg vs 6.48 mmHg; P = 0.800) in IPF patients with LTOT. Conversely, among IPF patients without LTOT, the adjusted annual change in PASP was significantly lower in the nintedanib group than in the no antifibrotic therapy group (0.26 mmHg vs 7.05 mmHg; P = 0.011). Adjusted annual change in PASP was assessed using a two-sample t-test. Two-sided P-values < 0.05 were considered significant